TABRECTA (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
TABRECTA
Date registered
Evaluation commenced
Decision date
Approval time
193 (255 working days)
Active ingredients
capmatinib hydrochloride
Registration type
NCE/NBE
Indication
TABRECTA® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation